Story perspectives

CK Life Sciences Fast Tracks Cancer Vaccines in China

3/30/2026

Summary

Story summary

CK Life Sciences plans to expedite its cancer vaccines in mainland China via a 'fast track' channel.
Dr. Melvin Toh, CK Life Sciences vice-president, announced investigator-initiated trials (IITs) within the next year.
Sequencio Therapeutics was established in Hong Kong to advance CK Life Sciences' cancer vaccine pipeline, including about 20 preclinical projects.
The two most advanced candidates are expected to enter trials by late 2027 or early 2028.

1 of 1

Story summary

CK Life Sciences plans to expedite its cancer vaccines in mainland China via a 'fast track' channel.
Dr. Melvin Toh, CK Life Sciences vice-president, announced investigator-initiated trials (IITs) within the next year.
Sequencio Therapeutics was established in Hong Kong to advance CK Life Sciences' cancer vaccine pipeline, including about 20 preclinical projects.
The two most advanced candidates are expected to enter trials by late 2027 or early 2028.